Lenvatinib plus pembrolizumab versus standard of care in recurrent/metastatic head and neck squamous cell carcinoma: Randomized, phase 2 LEAP-009 trial

By afschroeder • June 5, 2026

Kim HR, Oliva M, Salas S, Wong DJ, Even C, Kim JW, Kang M, Wu SY, Lauche O, Ahn MJ, Yang MH, Lien MY, Metcalf R, Clatot F, McGrath M, Webster M, Assaf JD, Rivas AS, Bernsdorf M, Billan S, Kaczmar J, Grose D, Jankowska P, Jelinek MJ, Ciuleanu TE, Vieira C, Dutcus C, Okpara CE, Wang G, Bidadi B, Gumuscu B, Harrington K. Lenvatinib plus pembrolizumab versus standard of care in recurrent/metastatic head and neck squamous cell carcinoma: Randomized, phase 2 LEAP-009 trial. Eur J Cancer. 2026 May 22;243:116824. doi: 10.1016/j.ejca.2026.116824. Epub ahead of print. PMID: 42241967.

Tags: Hematology/Oncology, lenvatinib, Multikinase inhibitor, PD-1 inhibitor, pembrolizumab, Publications, R/M HNSCC

Adjuvant Osimertinib in Resected EGFR-Mutated Stage IB-IIIA Non-Small Cell Lung Cancer: Exploratory 8-year Overall Survival Landmark Update from the ADAURA Trial [161/175]

Wu YL, Majem M, John T, Grohé C, Wang J, Goldman JW, Lu S, Shepherd FA, Wang Q, Kato T, Aokage K, Zhong WZ, Laktionov[...]

Management Patterns and Outcomes for Relapsed or Refractory Hodgkin Lymphoma

Paniker AG, Marshalek JP, Chao E, Yashar D, Tomassetti S. Management Patterns and Outcomes for Relapsed or Refractory Hodgkin Lymphoma. J Hematol. 2026 Aug 31;15(4):188-197.[...]

Advancing clinical trials for rare renal cell carcinoma subtypes: Consensus statements from the International Kidney Cancer Symposium North America 2025 think tank

Msaouel P, La Rosa S, Abel EJ, Albiges L, Barata PC, Berg SA, Braun DA, Brugarolas J, Campbell MT, Carlo MI, Coleman K, Cost NG,[...]